title: Tacrolimus analysis: a comparison of different methods and matrices.
abstract: We determined the through blood and plasma concentrations of tacrolimus from the day of transplantation through 30 days posttransplantation in four liver and four kidney transplant patients by three different methods. The first method involved a solid phase extraction of the blood or plasma using Sep-Pak columns (SPs) followed by quantitation of tacrolimus using an enzyme-linked immunosorbent assay (ELISA); the second method involved a liquid-liquid extraction using methylene chloride (MC) followed by quantitation of tacrolimus using the ELISA, and the third method involved a high-performance liquid chromatography (HPLC) fractionation of the extract obtained from the solid-phase extraction and quantitation of tacrolimus in the fractions by ELISA. The trough plasma tacrolimus concentrations ranged from 0.1 to 5.2 ng/ml. While the trough plasma concentrations of tacrolimus were similar and independent of the method of analysis in kidney transplant patients and in liver transplant patients with normal biochemical profile, in patients with liver dysfunction, tacrolimus plasma concentrations were higher when measured by SP-ELISA and MC-ELISA methods as compared to the HPLC-ELISA method. In plasma samples obtained from liver transplant patients with liver dysfunction, the presence of some metabolites that cross-reacted with the antibody used in the ELISA could be documented in the HPLC fraction corresponding to the metabolites. This indicates that while tacrolimus metabolites that cross-react significantly with the antibody used in the ELISA do not accumulate in kidney transplant patients, they can appear in the plasma of patients, they can appear in the plasma of patients with liver dysfunction. The trough blood tacrolimus concentrations in patients were significantly higher than the corresponding plasma concentrations and ranged from 1.4 to 107 ng/ml.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Pathology, University of Pittsburgh Medical Center, PA 15213-2582, USA.
authors.forename: V
authors.initials: V
authors.lastname: Warty
authors.forename: S
authors.initials: S
authors.lastname: Zuckerman
authors.forename: R
authors.initials: R
authors.lastname: Venkataramanan
authors.forename: J
authors.initials: J
authors.lastname: Lever
authors.forename: J
authors.initials: J
authors.lastname: Chao
authors.forename: T
authors.initials: T
authors.lastname: Mckaveney
authors.forename: J
authors.initials: J
authors.lastname: Fung
authors.forename: T
authors.initials: T
authors.lastname: Starzl
mesh_terms: D002851:Chromatography, High Pressure Liquid; D003404:Creatinine / Q000097:blood; D016903:Drug Monitoring; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood*; D016030:Kidney Transplantation; D016031:Liver Transplantation; D013619:Tacrine; D016559:Tacrolimus / Q000032:analysis* / Q000097:blood; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D013619:Tacrine; D003404:Creatinine; D016559:Tacrolimus